Bolt Biotherapeutics (BOLT) Equity Average (2020 - 2025)
Historic Equity Average for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to $35.5 million.
- Bolt Biotherapeutics' Equity Average fell 5506.84% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 5506.84%. This contributed to the annual value of $85.0 million for FY2024, which is 4021.43% down from last year.
- Bolt Biotherapeutics' Equity Average amounted to $35.5 million in Q3 2025, which was down 5506.84% from $42.8 million recorded in Q2 2025.
- In the past 5 years, Bolt Biotherapeutics' Equity Average ranged from a high of $299.6 million in Q2 2021 and a low of $35.5 million during Q3 2025
- Its 5-year average for Equity Average is $148.9 million, with a median of $135.2 million in 2023.
- As far as peak fluctuations go, Bolt Biotherapeutics' Equity Average surged by 60235.94% in 2021, and later plummeted by 5506.84% in 2025.
- Over the past 5 years, Bolt Biotherapeutics' Equity Average (Quarter) stood at $262.5 million in 2021, then crashed by 31.44% to $180.0 million in 2022, then tumbled by 33.05% to $120.5 million in 2023, then plummeted by 46.38% to $64.6 million in 2024, then plummeted by 45.1% to $35.5 million in 2025.
- Its Equity Average was $35.5 million in Q3 2025, compared to $42.8 million in Q2 2025 and $52.0 million in Q1 2025.